Market capitalisation
?
Share price multiplied by shares outstanding. It does not measure company cash.
Company analysis·AMGN
Preparing the analysis
We’re preparing the company’s analysis.
NASDAQ·AMGN
Amgen Inc.
Share price$456.36Price as of: Nov 9, 2026
Amgen Inc. (AMGN) is a company listed on NASDAQ, classified under Drug Manufacturers - General.
Amgen is a global biotechnology company offering a broad range of innovative medicines for inflammatory, oncology, bone, cardiovascular, and other conditions.
Revenue · FY 2025
?
Sales generated during the period, before costs and expenses.
Net margin · FY 2025
?
Net income as a proportion of revenue.
“Our take” and other explanations are generated with artificial intelligence from the data, without human review of each text. They are descriptive, not recommendations. Learn more
Explore questions
P1 · What does it do and how does it make money?
Of every $100 it takes in,20 come from Other Products.
Other Products is its largest source of revenue (19.8%), followed by Prolia (12.0%). Here you will see what it sells, where, and how that mix is changing.
$37bnrevenue in FY 2025
15business lines with data
72%of sales, in UNITED STATES
Full fiscal year ended Dec 31, 2025
After that close
Q3 2026, ended Sep 30, 2026: total revenue +8.5% against the same quarter a year earlier.
This is the revenue of the whole company. The split by lines and regions on this page is still that of the full fiscal year.01How it makes money
The data does not separate products from services.
Not all revenue behaves the same way. A one-off sale depends on someone buying again; a service is billed again and again while the customer stays.
Its business lines · FY 2025
02Where revenue comes from
Revenue is spread out.
Each rectangle is a business line and its size is the share of revenue it brings in. Select one to see the detail.
No room for a label in the mosaic
No breakdown3.8%
Area = share of total revenue for the year. It does not show profit: the company does not report what each line earns.
$1.4bn (3.8%) of revenue has no segment assigned in the published data.
What is a segment's weight?
The part of everything the company takes in that comes from that line. If a line weighs 49%, then of every 100 in sales, 49 come from it.
How to read it
The more a line weighs, the more revenue depends on it. A high weight is neither good nor bad by itself: it shows where to look first.
03Where sales come from
It depends on one main market.
UNITED STATES is its largest market, with 71.9% of sales. Each square is a region and its area is what it sells there.
Regions from largest to smallest · FY 2025
04How the mix is changing
ENBREL is losing weight.
Weight of each part in 2024 and in 2025. A line gains weight when it grows faster than the total.
pp = percentage points: the difference between two percentages (from 25% to 27% is 2 pp).
05Read with care
What we can deduce from the data. And what we cannot.
We can deduceWe cannot conclude
01
No single product dominates: the largest line is just 19.8% and the top three together 41.6%, across a broad portfolio.
That the business is highly diversified against commercial risk: without knowing customer or market concentration, the spread across lines does not guarantee it.
02
Other lines not only offset the drop in Enbrel and Xgeva (−$1.2B), but created net growth.
That all lines are equally resilient: if strong growth is limited to a few, offsetting power may not be broadly shared.
03
The company clearly depends on the US, which accounts for 71.9% of sales and 76.8% of annual growth.
That international performance could offset a US downturn: though it grows, its share of growth is notably less.
Our take
Amgen's 2025 growth relies chiefly on a mid-sized line and its regional concentration limits true risk diversification.
- 01Shown by the figures
Wide portfolio, clear regional dependency
No line dominates sales: the top three represent just 41.6%. However, the US concentrates over two-thirds of sales and driving growth.
What is not proven
What share of the total margin belongs to each line? Without it, the true contribution of each segment to profit remains unknown.
See the calculations behind it
- Other Products brought $1.6B of the $3.3B by which revenue grew in FY 2025 (49.2%), although it weighed 16.8%. Without that line, the rest grew 6.1%.
- No line dominates: the largest, Other Products, weighs 19.8% (16.8% in FY 2024) and the top three add up to 41.6% across 15 lines.
- Enbrel and Xgeva took away $1.2B in FY 2025; the other lines made up for it and revenue still rose $3.3B.
- United States brings 71.9% of sales (71.4% in FY 2024).
- Other Products accounts for 49.2% of the change in revenue in FY 2025 and weighed 16.8%.
- United States brought 76.8% of the growth in sales by region in FY 2025, weighing 71.4%.
With data to Nov 4, 2026. Analysis written by a language model from our calculations, which supply every figure. It is not investment advice.
Next step